Enovis (ENOV) Competitors $28.44 +2.69 (+10.42%) Closing price 08/7/2025 03:59 PM EasternExtended Trading$28.53 +0.09 (+0.30%) As of 08:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENOV vs. BC, DOV, ITT, IRTC, GKOS, BLCO, SLNO, TMDX, INSP, and NVSTShould you be buying Enovis stock or one of its competitors? The main competitors of Enovis include Brunswick (BC), Dover (DOV), ITT (ITT), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), Inspire Medical Systems (INSP), and Envista (NVST). Enovis vs. Its Competitors Brunswick Dover ITT iRhythm Technologies Glaukos Bausch + Lomb Soleno Therapeutics TransMedics Group Inspire Medical Systems Envista Enovis (NYSE:ENOV) and Brunswick (NYSE:BC) are related companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment. Do analysts rate ENOV or BC? Enovis presently has a consensus target price of $55.00, suggesting a potential upside of 93.36%. Brunswick has a consensus target price of $68.25, suggesting a potential upside of 19.51%. Given Enovis' stronger consensus rating and higher probable upside, research analysts plainly believe Enovis is more favorable than Brunswick.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enovis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Brunswick 0 Sell rating(s) 6 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.54 Which has more risk & volatility, ENOV or BC? Enovis has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Brunswick has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Does the media refer more to ENOV or BC? In the previous week, Brunswick had 2 more articles in the media than Enovis. MarketBeat recorded 10 mentions for Brunswick and 8 mentions for Enovis. Brunswick's average media sentiment score of 0.79 beat Enovis' score of 0.51 indicating that Brunswick is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enovis 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Brunswick 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, ENOV or BC? Brunswick has higher revenue and earnings than Enovis. Enovis is trading at a lower price-to-earnings ratio than Brunswick, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnovis$2.11B0.77-$825.49M-$13.95-2.04Brunswick$5.10B0.73$130.10M$0.6292.11 Do insiders and institutionals hold more shares of ENOV or BC? 98.5% of Enovis shares are owned by institutional investors. Comparatively, 99.3% of Brunswick shares are owned by institutional investors. 2.7% of Enovis shares are owned by company insiders. Comparatively, 0.8% of Brunswick shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is ENOV or BC more profitable? Brunswick has a net margin of 0.82% compared to Enovis' net margin of -37.65%. Brunswick's return on equity of 10.73% beat Enovis' return on equity.Company Net Margins Return on Equity Return on Assets Enovis-37.65% 5.99% 3.44% Brunswick 0.82%10.73%3.54% SummaryBrunswick beats Enovis on 11 of the 16 factors compared between the two stocks. Get Enovis News Delivered to You Automatically Sign up to receive the latest news and ratings for ENOV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENOV vs. The Competition Export to ExcelMetricEnovisMEDICAL INFO SYS IndustryMedical SectorNYSE ExchangeMarket Cap$1.47B$1.99B$5.48B$20.70BDividend YieldN/AN/A3.99%3.66%P/E Ratio-2.0434.4029.9328.65Price / Sales0.7748.98375.2268.85Price / Cash1.3450.3435.9423.59Price / Book0.639.088.104.32Net Income-$825.49M-$63.67M$3.26B$995.66M7 Day Performance10.51%1.36%0.68%1.91%1 Month Performance-18.12%-0.62%2.45%-0.54%1 Year Performance-34.73%19.27%27.72%14.76% Enovis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENOVEnovis3.3614 of 5 stars$28.45+10.4%$55.00+93.4%-29.8%$1.47B$2.11B-2.047,367News CoverageEarnings ReportAnalyst ForecastBCBrunswick4.0615 of 5 stars$58.81+3.8%$68.25+16.1%-22.8%$3.70B$5.10B94.8515,000DOVDover4.7489 of 5 stars$176.09+0.6%$213.92+21.5%+0.8%$23.99B$7.75B10.6224,000ITTITT4.2326 of 5 stars$166.88+1.7%$179.22+7.4%+29.3%$12.80B$3.63B26.2411,700Trending NewsDividend AnnouncementAnalyst RevisionIRTCiRhythm Technologies1.8142 of 5 stars$164.98+0.0%$157.30-4.7%+135.0%$5.30B$591.84M-56.312,000Insider TradeGKOSGlaukos4.0015 of 5 stars$87.52+1.6%$127.42+45.6%-24.1%$4.92B$383.48M-53.04780BLCOBausch + Lomb3.1004 of 5 stars$13.76+1.9%$15.56+13.0%-10.0%$4.78B$4.79B-17.6413,500SLNOSoleno Therapeutics4.5817 of 5 stars$84.12-2.2%$108.70+29.2%+79.0%$4.33BN/A-18.2130News CoveragePositive NewsEarnings ReportAnalyst ForecastTMDXTransMedics Group2.6411 of 5 stars$128.50+6.6%$123.00-4.3%-20.4%$4.11B$441.54M66.58210INSPInspire Medical Systems4.64 of 5 stars$130.79+3.7%$208.55+59.5%-59.1%$3.72B$802.80M60.271,246Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHigh Trading VolumeNVSTEnvista3.4903 of 5 stars$20.48-1.7%$20.92+2.2%+31.2%$3.46B$2.51B63.9912,300 Related Companies and Tools Related Companies Brunswick Competitors Dover Competitors ITT Competitors iRhythm Technologies Competitors Glaukos Competitors Bausch + Lomb Competitors Soleno Therapeutics Competitors TransMedics Group Competitors Inspire Medical Systems Competitors Envista Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ENOV) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
